(+) Study shows promise for topical application of living skin cells following laser treatment (PRWeb) - Apr 23, 2012 - Dr. David McDaniel announced preliminary data supporting the potential for topical ‘needle free' application of human skin fibroblast cells following fractional laser treatment; The data was presented Saturday as a "Late-Breaker" at the 2012 American Society for Laser Medicine and Surgery annual meeting in Kissimmee, FL; Pre-treatment with a 2940nm wavelength fractional skin resurfacing laser effectively enabled the topical application of fibroblast cells in a study of fresh skin samples; This laser was used to create precise microchannels in the skin to enable delivery of fibroblast cells into the skin; The Palomar LUX2940 laser is FDA cleared and is intended for use in dermatological procedures requiring coagulation, resurfacing, and ablation of soft tissue
Data presentation • Fibrosis
|
|
Virginia Beach, VA (PRWEB) April 23, 2012
Dr. David McDaniel today announced preliminary data supporting the potential for topical ‘needle free’ application of human skin fibroblast cells following fractional laser treatment. The data was presented Saturday as a “Late-Breaker” at the 2012 American Society for Laser Medicine and Surgery annual meeting in Kissimmee, FL. Azficel-T (LAVIVTM) is currently available as an injectable treatment for the improvement of the appearance of moderate-to-severe nasolabial fold (“smile line”) wrinkles. LAVIV is made from a person’s own living, cultured, collagen-producing fibroblast cells and is the first and only personalized cell therapy approved by the FDA for aesthetic use.
In an oral presentation accompanied by an “e-poster,” David H. McDaniel, M.D., assistant professor of Clinical Dermatology at Eastern Virginia Medical School and adjunct assistant professor in the Department of Biological Sciences at Old Dominion University, reported that pre-treatment with a 2940nm (nanometer) wavelength fractional skin resurfacing laser effectively enabled the topical application of fibroblast cells in a study of fresh skin samples. This laser was used to create precise microchannels in the skin to enable delivery of fibroblast cells into the skin. The Palomar LUX2940 laser is FDA cleared and is intended for use in dermatological procedures requiring coagulation, resurfacing, and ablation of soft tissue.
“Topical application of fibroblasts may be a viable option for people who prefer laser therapy over needle injections, plus this laser therapy has the benefit of stimulating collagen, itself, as well as improving uneven skin pigmentation,” commented Dr. McDaniel, who is also director of the Laser and Cosmetic Center and the McDaniel Institute of Anti-Aging Research, and co-director of the Hampton University Skin of Color Research Institute in Virginia. “What’s really exciting about this research is the potential to treat with a fractional laser and then apply fibroblast cells to the entire face rather than just treating individual lines and wrinkles. There is great potential for treating aging skin over extensive areas such as the décolleté and hands. In theory, we could deliver millions and millions of a person’s own cells via tens of thousands of microchannels – a technique you might call cell renewal therapy. I’m excited about moving this research forward in the future.”
|